9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering Advances in Optical Genome Mapping for Hematologic Malignancies

Rhea-AI Summary

Bionano Genomics (Nasdaq: BNGO) reported Day 1 highlights from Symposium 2026 focused on optical genome mapping (OGM) for hematologic malignancies. Nine presentations showed OGM's high concordance with traditional cytogenetics and its ability to resolve complex structural variants, integrate with NGS via VIA, and rescue failed assays.

More than 1,000 attendees from 70 countries participated; session recordings will be available on the company YouTube channel, with the live panel Q&A excluded from on-demand.

Key Figures

Symposium attendees: >1000 registrants Countries represented: 70 countries Continents represented: 6 continents +3 more

6 metrics

Symposium attendees >1000 registrants Bionano Symposium 2026 Day 1

Countries represented 70 countries Symposium 2026 attendance

Continents represented 6 continents Symposium 2026 attendance

Day 1 presenters 9 presenters Hematologic malignancies OGM session

Day 2 time 7:00–10:00 AM PT Day 2: New Frontiers in Oncology and Bioprocessing

Registration fee $0 Symposium registration open to all

Market Reality Check

Price: $1.13 Vol: Volume 89,874 vs 20-day a...

low vol

$1.13 Last Close

Volume Volume 89,874 vs 20-day average 236,284 (relative volume 0.38x) suggests limited pre-news participation. low

Technical Shares at $1.125 trade below the $2.48 200-day MA and sit close to the $1.06 52-week low (52-week high $5.50).

Peers on Argus

BNGO slipped 0.88% while momentum scanners only flagged peer LUCY moving up and ...

1 Up

BNGO slipped 0.88% while momentum scanners only flagged peer LUCY moving up and most listed peers showed mixed, stock-specific moves rather than a coordinated sector trend.

Historical Context

5 past events · Latest: Feb 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 09	Symposium announcement	Positive	+0.0%	Announced free virtual Bionano Symposium 2026 with >30 OGM-focused sessions.
Feb 04	OGM study results	Positive	-1.3%	Peer-reviewed study showed OGM detects low-frequency genomic alterations from gene editing.
Jan 12	Prelim financial results	Negative	+0.6%	Preliminary Q4 and FY2025 revenue declined year over year with modest system growth.
Dec 11	Conference recap	Positive	-1.2%	Recap of AMP 2025 studies showing expanded OGM use across multiple disease areas.
Dec 03	Reimbursement update	Positive	+3.0%	CMS increased CPT 81195 OGM payment by 47%, supporting higher reimbursement levels.

Pattern Detected

News on OGM technology and reimbursement has often been positive in tone, but price reactions have frequently diverged, especially on scientific updates and preliminary financials.

Recent Company History

Over the last few months, Bionano has highlighted OGM adoption across conferences and peer-reviewed studies, alongside preliminary Q4/FY2025 results showing revenue declines. A key milestone was the 47% increase in CMS payment for CPT code 81195 effective Jan 1, 2026, which drew a positive share reaction. Today’s Symposium 2026 Day 1 update continues the theme of expanding OGM use in hematologic malignancies, extending earlier event and conference messaging about integration into cytogenetics workflows.

Market Pulse Summary

This announcement highlights expanding real-world use of OGM in hematologic malignancies, with >1000...

Analysis

This announcement highlights expanding real-world use of OGM in hematologic malignancies, with >1000 registrants from 70 countries and 9 Day 1 talks spanning CLL, non-Hodgkin lymphoma, and multiple myeloma. The focus on integrating OGM with NGS and VIA software reinforces Bionano’s strategy already seen in past conference updates and reimbursement wins. Investors may watch for how this growing academic and clinical interest ultimately connects to system placements, utilization, and future revenue disclosures.

Key Terms

optical genome mapping, cytogenetic, structural variants, fluorescence in-situ hybridization, +3 more

7 terms

optical genome mapping medical

"advancements in Hematologic Malignancies with Optical Genome Mapping (OGM)."

Optical genome mapping is a laboratory technique that produces a high-resolution picture of a person’s long DNA strands to find large structural changes such as missing, extra, or rearranged pieces. For investors, it matters because the method can improve diagnosis, speed development of genetic tests and therapies, and influence regulatory approvals and market demand for companies offering more accurate or faster genomic tools — think of it as a wide-angle camera that reveals large-scale defects traditional microscopes might miss.

cytogenetic medical

"reshaping cytogenetic and molecular workflows by detecting critical structural variants"

Relating to the study of cells’ chromosomes — the bundled packages of DNA that act like a building’s blueprint for traits and behavior. Cytogenetic information shows whether those blueprints have missing, extra, or rearranged pieces, which can affect disease diagnosis, how patients respond to treatments, and whether a therapy is safe; for investors, that data can influence clinical trial outcomes, regulatory approval chances, and market potential.

structural variants medical

"detecting critical structural variants and accelerating the precision and depth"

Structural variants are large-scale changes in an organism’s DNA—such as missing, extra, flipped, or rearranged chunks of genetic material—that are like tearing out, duplicating, or reshuffling chapters in a book. Investors should care because these changes can drive or explain diseases, alter how well diagnostics and therapies work, and shift the commercial and regulatory outlook for drugs, tests, and gene-based treatments.

fluorescence in-situ hybridization medical

"traditional cytogenetic and molecular techniques, including karyotyping (KT), fluorescence in-situ hybridization (FISH)"

Fluorescence in-situ hybridization is a laboratory technique that uses glowing molecular probes to find and highlight specific DNA or RNA sequences inside cells, like placing colored sticky notes on particular sentences in a large book. For investors, it matters because the test can diagnose diseases, identify genetic targets for therapies, and serve as a companion diagnostic that influences clinical decisions, regulatory approval and commercial value for biotech and diagnostics firms.

next-generation sequencing medical

"traditional cytogenetic and molecular techniques, including karyotyping (KT), fluorescence in-situ hybridization (FISH), and next-generation sequencing (NGS)."

Next-generation sequencing is a set of laboratory techniques that read large amounts of DNA or RNA quickly and cheaply by processing millions of short genetic fragments in parallel, rather than one at a time. For investors, it matters because faster, lower-cost genetic data powers drug discovery, diagnostic tests and personalized medicine, creating scalable revenue opportunities and competitive advantages for companies that own the technology or services.

chromoanagenesis medical

"covered particularly challenging subtypes and variant classes, including: pediatric acute lymphoblastic leukemiachromoanagenesis in CLL"

Chromoanagenesis is a sudden, catastrophic reshuffling of one or a few chromosomes where DNA is broken and stitched back together in the wrong order, creating many complex mutations in a single event. It matters to investors because this kind of genome damage can drive aggressive disease, alter how patients respond to treatments, and affect the value of diagnostics or therapies tied to specific genetic targets — like a book whose pages are torn out and randomly reinserted, changing the story.

rna sequencing medical

"shared comparative data between targeted RNA sequencing and OGM for detecting pathogenic"

RNA sequencing is a laboratory method that reads the active genetic messages inside cells, like scanning the recipe cards a cell is using at a given moment to make proteins. For investors, it matters because the results can reveal how diseases operate, identify targets for new drugs or diagnostics, and help companies show whether a treatment is working—information that can change a biotech firm's value much like a new product test result can affect a tech stock.

AI-generated analysis. Not financial advice.

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 1 of the Bionano Symposium 2026 entitled Advancements in Hematologic Malignancies with Optical Genome Mapping (OGM). Hematologic malignancies are cancers of the blood and lymph systems. Today’s virtual session brought together global experts and key opinion leaders who shared new data demonstrating how OGM is reshaping cytogenetic and molecular workflows by detecting critical structural variants and accelerating the precision and depth of genomic analysis of leukemias, lymphomas, and multiple myeloma. There are more than 1000 registered attendees from 70 countries across 6 continents for Symposium 2026, making it the single largest event dedicated to OGM and Bionano solutions during the 2026 conference calendar.

9 presenters from leading academic medical and cancer centers across Europe and the U.S., including Alka Chaubey, Ph.D., FACMG, Bionano’s chief medical officer showcased how OGM works and how it can deliver enhanced resolution, sensitivity, and comprehensive structural variant detection for clinical research compared with traditional cytogenetic and molecular techniques, including karyotyping (KT), fluorescence in-situ hybridization (FISH), and next-generation sequencing (NGS). They reported high concordance between OGM and traditional cytogenetics methods while emphasizing OGM’s ability to resolve complex rearrangements, identify novel driver events, and rescue cases with failed conventional cytogenetics. Speakers underscored the growing role of OGM as an integrated component of modern hematologic malignancy research, often in combination with next generation sequencing (NGS) and analysis in VIA^TM software, Bionano’s solution for integrated visualization, interpretation, and reporting of genomic variants.

Among key presentations on the day, Dr. Chaubey kicked off the content by outlining how OGM works and presenting recent technological advancements for the OGM workflow. Her talk presented many publications that suggest an expanding role of OGM in hematologic malignancy research and cytogenomics as part of a transformation of pathology workflows from analog legacy methods to more up-to-date digital workflows.

Dr. Ravindra Kolhe (Augusta University) presented comparative hematologic malignancy workflows in molecular pathology and cytogenetics where OGM was compared to traditional cytogenetic methods like KT, FISH and a 523-gene NGS panel. Dr. Kolhe highlighted the integration of OGM and NGS within VIA for comprehensive cancer genomics analysis. His presentation illustrated how combining sequence- and structure variant-based technologies can enable deeper insight into complex genomic events.

Dr. Wahab A. Khan (Dartmouth-Hitchcock Medical Center) presented exploratory genomic profiling in chronic lymphocytic leukemia (CLL), demonstrating how OGM can quickly and more accurately uncover cryptic, complex, and pathogenic SVs or rearrangements not detected by standard cytogenetic methods.  

Amber Verhasselt (KU Leuven) showed how OGM can identify pathogenic aberrations in non-Hodgkin lymphoma across multiple challenging specimen types while revealing additional biologically relevant findings beyond conventional workflows.

Dr. Gokce A. Toruner (The University of Texas MD Anderson Cancer Center) shared comparative data between targeted RNA sequencing and OGM for detecting pathogenic gene rearrangements, demonstrating the complementary strengths of both technologies.

Dr. Elly De Vlieghere (AZ Sint-Jan Brugge) demonstrated how OGM can replace multiple traditional assays for molecular cytogenetic analysis in multiple myeloma (MM), a challenging plasma cell neoplasm, by employing a modified workflow for OGM to yield more answers.

Dr Rashmi Kanagal Shamanna (The University of Texas MD Anderson Cancer Center) showcased the expert recommendations from the International Consortium of OGM (ICOGM; www.icogm.org) regarding the use of OGM in several subtypes of heme malignancies in research applications.

In addition to the more common hematologic malignancies, presentations from Klaudia Starosz (Medical University of Lodz) and Anna Maria Puiggros (Hospital del Mar) also covered particularly challenging subtypes and variant classes, including:

• pediatric acute lymphoblastic leukemia
• chromoanagenesis in CLL
  
  

The session concluded with a live panel discussion and Q&A session with speakers and moderated by Bionano’s Dr. Chaubey, Dr. Andy O’Shaughnessy, Dr. Dana Jaber, and Cami Asher. Panelists discussed best practices for implementation, validation strategies, and the future role OGM may play in routine hematologic malignancy research.

“We are so inspired by the quality and breadth of research shared by the global OGM community during Day 1 of Symposium 2026,” said Dr. Chaubey. “Collectively, Day 1 presentations reinforced the potential of OGM as a powerful tool for comprehensive cytogenomic analysis in hematologic malignancies, offering improved detection of structural variants, enhanced interpretation of complex rearrangements, and new unbiased insights into disease biology and oncology research. It’s amazing to see how OGM and VIA software are being successfully implemented across diverse laboratory settings around the world to transform landscape in cytogenetics and molecular pathology.”

“What impresses me most about today’s talks is how far the community has come with application of OGM to hematologic malignancies,” said Erik Holmlin, president and chief executive officer of Bionano. “These findings show that OGM can play a key role in unraveling the complexity of large genomic rearrangements and revealing previously undetected variants, while VIA software makes it possible to integrate OGM and NGS data in a single view to help guide a deeper understanding of disease. Our mission is to transform how the world sees the genome, and we can see this transformation unfolding right here at Symposium 2026.”

Session recordings will be available on-demand via the Bionano YouTube channel. The live panel discussion and Q&A session will not be available on demand.

Bionano Symposium 2026 continues with Day 2: New Frontiers in Oncology and Bioprocessing Applications on February 24, 2026, from 7:00-10:00 AM PT. Attendees may also explore scientific posters available throughout the event on the virtual platform.

Don’t miss the Bionano Symposium 2026, register now! Symposium registration is open to all and there is no charge for attending this event. To register, visit:
www.bionano.com/symposium-2026

About Bionano Genomics

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit www.bionano.com or www.bionanolaboratories.com.
Bionano’s products are for research use only and not for use in diagnostic procedures.

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things; the ability and utility of OGM to deliver enhanced resolution, sensitivity, and comprehensive structural variant detection compared with traditional cytogenetic and molecular techniques, including KT, FISH, and NGS; the ability and utility of OGM to deliver high concordance with traditional cytogenetics methods; the ability and utility of OGM to resolve complex rearrangements, identify novel driver events, and rescue cases with failed conventional cytogenetics; the ability and utility of OGM when paired with sequencing to provide deeper insights into complex genomic events; the ability and utility of OGM to play a role in expanding hematologic malignancy research and cytogenomics as part of a transformation of pathology workflows from analog legacy methods to more up-to-date digital workflows; the ability and utility of OGM in uncovering cryptic and complex rearrangements not detected by standard cytogenetic methods; the ability and utility of OGM in identifying pathogenic aberrations in non-Hodgkin lymphoma across multiple challenging specimen types while revealing additional biologically relevant findings beyond conventional workflows; the potential of OGM as a powerful tool for comprehensive cytogenomic analysis in hematologic malignancies, offering improved detection of structural variants, enhanced interpretation of complex rearrangements, and new unbiased insights into disease biology and oncology research; continued research, presentations and publications involving OGM, its utility compared to traditional cytogenetics and our technologies; and our ability to drive adoption of OGM and our technology solutions and any other statements that are not of historical fact. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the failure of OGM to deliver enhanced resolution, sensitivity, and comprehensive structural variant detection compared with traditional cytogenetic and molecular techniques, including KT, FISH, and NGS; the failure of OGM to deliver high concordance with traditional cytogenetics methods; failure of OGM to resolve complex rearrangements, identify novel driver events, and rescue cases with failed conventional cytogenetics; the failure of OGM when paired with sequencing to provide deeper insights into complex genomic events; the failure of OGM to play a role in expanding hematologic malignancy research and cytogenomics as part of a transformation of pathology workflows from analog legacy methods to more up-to-date digital workflows; the failure of OGM to uncover cryptic and complex rearrangements not detected by standard cytogenetic methods; the failure OGM to identifying pathogenic aberrations in non-Hodgkin lymphoma across multiple challenging specimen types while revealing additional biologically relevant findings beyond conventional workflows; the failure of OGM to become a powerful tool for comprehensive cytogenomic analysis in hematologic malignancies, offering improved detection of structural variants, enhanced interpretation of complex rearrangements, and new unbiased insights into disease biology and oncology research our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern,” which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the impact of adverse geopolitical and macroeconomic events and uncertain market conditions, including inflation, tariffs, and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; study results that differ or contradict the results mentioned in this press release and at Day 1 of Symposium 2026; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties including those described in our filings with the Securities and Exchange Commission (“SEC”), including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:
Kelly Gura
Gilmartin Group
+1 (212) 229-6163
IR@bionano.com

FAQ

What key findings about OGM were presented at the Bionano Symposium 2026 (BNGO) Day 1?

Presenters reported OGM shows high concordance with cytogenetics while resolving complex structural variants more effectively. According to the company, nine academic talks detailed OGM detecting novel drivers, rescuing failed assays, and complementing NGS for deeper hematologic malignancy analysis.

How does Bionano say VIA software integrates OGM and NGS data for researchers (BNGO)?

VIA enables integrated visualization and interpretation of sequence and structural variants in a single view. According to the company, presenters showed VIA combining OGM and NGS to streamline comprehensive cancer genomics and improve reporting workflows across labs.

Who presented clinical applications of OGM at Symposium 2026 Day 1 relevant to leukemias and lymphomas (BNGO)?

Nine speakers from leading academic centers presented applications across leukemia, lymphoma, and multiple myeloma. According to the company, talks included CLL, non-Hodgkin lymphoma, MM, pediatric ALL, and comparative studies versus KT, FISH, and targeted NGS panels.

Will Day 1 session recordings from Bionano Symposium 2026 (BNGO) be available on demand?

Most session recordings will be available on demand via the company YouTube channel, but the live panel Q&A will not be available. According to the company, recordings of presentations will be posted for registered attendees and the wider public.

How large was attendance for Bionano Symposium 2026 Day 1 and what does that signify for OGM adoption (BNGO)?

Day 1 drew over 1,000 registered attendees from 70 countries, indicating growing global interest in OGM. According to the company, this was the largest OGM-focused event in the 2026 conference calendar, reflecting expanding research adoption and research community engagement.

When is Day 2 of Bionano Symposium 2026 and what topics will it cover (BNGO)?

Day 2 is scheduled for February 24, 2026, from 7:00–10:00 AM PT and focuses on oncology and bioprocessing applications. According to the company, Day 2 continues virtual sessions, poster access, and additional scientific presentations for registered attendees.